



MEDICAL POLICY STATEMENT WEST VIRGINIA MARKETPLACE PLANS

| | | |
|----------------------------|---------------------------|-----------------------|
| Original Issue Date | Next Annual Review | Effective Date |
| 07/20/2003 | 11/01/2019 | 11/01/2018 |
| Policy Name | | Policy Number |
| Breast Reduction Surgery | | MM-0248 |
| Policy Type | | |
| MEDICAL | Administrative | Pharmacy |
| | | Reimbursement |

Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.

Contents of Policy

| | |
|-----------------------------------------|---|
| <u>MEDICAL POLICY STATEMENT</u> | 1 |
| <u>TABLE OF CONTENTS</u> | 1 |
| <u>A. SUBJECT</u> | 2 |
| <u>B. BACKGROUND</u> | 2 |
| <u>C. DEFINITIONS</u> | 2 |
| <u>D. POLICY</u> | 3 |
| <u>E. CONDITIONS OF COVERAGE</u> | 5 |
| <u>F. RELATED POLICIES/RULES</u> | 5 |
| <u>G. REVIEW/REVISION HISTORY</u> | 5 |
| <u>H. REFERENCES</u> | 5 |



A. SUBJECT

Breast Reduction Surgery

B. BACKGROUND

Reduction mammoplasty is a surgical procedure performed to reduce the volume and weight of the female breasts. It may be performed for a variety of reasons, including relief of physical symptoms, relief of psychological symptoms, or as a cosmetic procedure based on the patient's preference for smaller breast size. Reduction Mammoplasty is among the most commonly performed cosmetic procedures in the United States. Female symptomatic breast hypertrophy can have both physical and psychosocial manifestations. In addition, some patients report impairment in lifting or participating in exercise and other physical activities. Patients may also report low self-esteem and dissatisfaction with body image. Given these consequences, female symptomatic macromastia or breast hypertrophy is recognized as a medical condition that requires treatment. Reduction Mammoplasty performed solely for cosmetic indications is considered by CareSource not to be a medically necessary treatment of disease.

Macromastia is the development of abnormally large breasts in the member as a result of breast hypertrophy. This condition can cause a variety of clinical manifestations when the weight of the excessive breast tissue adversely impacts supporting structures of the shoulders, neck and trunk. Macromastia is distinguished from large normal breasts by the presence of persistent symptoms. For the purpose of this policy, macromastia is considered the primary cause for the signs, symptoms and functional impairment being described. Reduction Mammoplasty is effective in relieving the symptoms of macromastia.

C. DEFINITIONS

- **Macromastia (Breast Hypertrophy):** An increase in the volume and weight of breast tissue relative to the general body habitus.
- **Functional/Physical or Physiological Impairment:** Physical/functional or physiological impairment causes deviation from the normal function of a tissue or organ. This results in a significantly limited, impaired, or delayed capacity to move, coordinate actions, or perform physical activities and is exhibited by difficulties in one or more of the following areas: physical and motor tasks; independent movement; performing basic life functions.
- **Symptomatic Breast Hypertrophy:** A syndrome of persistent neck and shoulder pain, painful shoulder grooving from brassiere straps, chronic intertriginous rash of the infra-mammary fold and/or frequent episodes of headache, backache, and upper extremity neuropathies caused by an increase in the volume and weight of breast tissue beyond normal proportions.
- **Cellulitis:** An acute spreading bacterial infection in the deeper layers of skin associated with an abrasion or cut and characterized by redness, warmth, and swelling.
- **Intertriginous Rash:** Dermatitis occurring between juxtaposed folds of skin, caused by retention of moisture and warmth, and providing an environment favoring overgrowth of normal skin micro-organisms.
- **Kyphosis:** Over-curvature of the thoracic vertebrae (upper back), associated with: degenerative diseases such as arthritis; developmental problems; or with osteoporotic compression fractures of vertebral bodies.
- **The Schnur Sliding Scale:** Has been promoted for use in calculating the amount of breast tissue to be removed in reduction mammoplasty (Appendix A).
- **Cosmetic Procedures:** Procedures that correct an anatomical congenital anomaly without improving or restoring physiologic function are considered Cosmetic Procedures. The fact that a Covered Person may suffer psychological consequences or socially avoidant behavior as a result of an injury, sickness or congenital anomaly does not classify surgery or other procedures done to relieve such consequences or behavior as a reconstructive procedure



D. POLICY

- I. CareSource considers *breast reduction surgery medically necessary for non-cosmetic indications for members age 18 or older, or for whom growth is complete, when **ALL** of the following are present:*
 - A. *Breast size interferes with activities of daily living, as indicated by **1 or more** of the following:*
 1. *Arm numbness consistent with brachial plexus compression syndrome*
 2. *Cervical pain*
 3. *Chronic breast pain*
 4. *Headaches;*
 5. *Nipple position greater than 21 cm below suprasternal notch*
 6. *Persistent redness and erythema (intertrigo) below breasts*
 7. *Restriction of physical activity*
 8. *Severe bra strap grooving or ulceration of shoulder*
 9. *Shoulder pain*
 10. *Thoracic kyphosis*
 11. *Upper or lower back pain*
 - B. *Failure to relieve symptoms with nonsurgical treatment that includes **1 or more** of the following:*
 1. *Four to eight visits of physical therapy or chiropractic care, and 2 to 4 months of home exercise for cervical, shoulder or upper or lower back pain*
 2. *Medically supervised weight loss program for at least 3 months for overweight or obese patient*
 3. *Topical and oral antifungal agents for intertrigo*
 4. *Trial of nonsteroidal anti-inflammatory drugs to treat pain in neck, shoulder, upper or lower back, or breast*
 5. *Wound care for skin ulceration*
 6. *Appropriate bra support for at least 3 months (i.e. properly fitting with wide straps)*
 - C. *Preoperative evaluation by surgeon concludes that amount of breast tissue to be removed (by mass or volume) will provide a reasonable expectation of symptomatic relief*
 1. *The Schnur Sliding Scale is an evaluation tool used to determine the appropriate volume of tissue to be removed relative to a patient's total body surface area (BSA).*
 2. *This estimation can be instrumental in determining whether breast reduction surgery is being planned for cosmetic reasons or as a medically necessary procedure. In a survey of plastic surgeons utilizing this scale, Schnur et al.(1991) determined that a member whose removed breast weight was above the 22nd percentile were likely to receive the procedure for medical reasons. The weight of tissue to be removed from each breast must be above the 22nd percentile on the Schnur Sliding Scale (Appendix A below) based on the individual's body surface area (BSA).*
 3. *The body surface area in meters squared (m²) is calculated using the Mosteller formula as follows:*
 - 3.1 *Square root of height (inches) x weight (lbs.) divided by 3,131*
 - D. *No evidence of breast cancer*
 1. *As evidenced by results of a physical exam completed by a physician within the last year if under 40*
 2. *Women 40 to 54 years of age or older must have documentation of a mammogram negative for cancer performed within the year prior to the date of the planned breast reduction surgery.*
 3. *Women 55 and older may switch to mammograms every 2 years*



E. Breast reduction surgery following mastectomy to achieve symmetry is covered as part of the Women’s Health and Cancer Rights Act (WHCRA). Please refer to the CareSource Medical policy titled Breast Reconstruction Post Mastectomy for additional information.

Appendix A: **Schnur Sliding Scale**

| Body Surface Area and Minimum Requirement for Breast Tissue Removal | |
|---------------------------------------------------------------------|---------------------------------------------------------|
| Body Surface Area m ² | Grams per Breast of Minimum Breast Tissue to be Removed |
| 1.350-1.374 | 199 |
| 1.375-1.399 | 208 |
| 1.400-1.424 | 218 |
| 1.425-1.449 | 227 |
| 1.450-1.474 | 238 |
| 1.475-1.499 | 249 |
| 1.500-1.524 | 260 |
| 1.525-1.549 | 272 |
| 1.550-1.574 | 284 |
| 1.575-1.599 | 297 |
| 1.600-1.624 | 310 |
| 1.625-1.649 | 324 |
| 1.650-1.674 | 338 |
| 1.675-1.699 | 354 |
| 1.700-1.724 | 370 |
| 1.725-1.749 | 386 |
| 1.750-1.774 | 404 |
| 1.775-1.799 | 422 |
| 1.800-1.824 | 441 |
| 1.825-1.849 | 461 |
| 1.850-1.874 | 482 |
| 1.875-1.899 | 504 |
| 1.900-1.924 | 527 |
| 1.925-1.949 | 550 |
| 1.950-1.974 | 575 |
| 1.975-1.999 | 601 |
| 2.000-2.024 | 628 |
| 2.025-2.049 | 657 |
| 2.050-2.074 | 687 |



| | |
|------------------|------|
| 2.075-2.099 | 717 |
| 2.100-2.124 | 750 |
| 2.125-2.149 | 784 |
| 2.150-2.174 | 819 |
| 2.175-2.199 | 856 |
| 2.200-2.224 | 895 |
| 2.225-2.249 | 935 |
| 2.250-2.274 | 978 |
| 2.275-2.299 | 1022 |
| 2.300-2.324 | 1068 |
| 2.325-2.349 | 1117 |
| 2.350-2.374 | 1167 |
| 2.375-2.399 | 1219 |
| 2.400-2.424 | 1275 |
| 2.425-2.449 | 1333 |
| 2.450-2.474 | 1393 |
| 2.475-2.499 | 1455 |
| 2.500-2.524 | 1522 |
| 2.525-2.549 | 1590 |
| 2.550 or greater | 1662 |

E. CONDITIONS OF COVERAGE

HCPCS
 CPT

AUTHORIZATION PERIOD

F. RELATED POLICIES/RULES


N/A

G. REVIEW/REVISION HISTORY

| | DATE | ACTION |
|-----------------------|--------------------------------------------------------|-------------|
| Date Issued | 07/20/2003 | New Policy. |
| Date Revised | 07/1/2009, 07/2011, 02/2012, 07/2013, 12/31/2014 | |
| Date Effective | 1/01/2018 | |

H. REFERENCES

1. Howrigan P. Reduction and augmentation mammoplasty. *Obstet Gynecol Clin North Am.* 1994; 21(3): 539-543.



2. Miller AP, Zacher JB, Berggren RB, et al. Breast reduction for symptomatic macromastia. Can objective predictors for operative success be identified? *Plastic Reconstruct Surg.* 1995; 95(1):77-83.
3. Schnur PL, Hoehn JG, Ilstrup DM, et al. Reduction mammoplasty: Cosmetic or reconstructive procedure? *Ann Plastic Surg.* 1991; 27(3):232-237.
4. Mosteller RD: Simplified Calculation of Body Surface Area. *N Engl J Med* 1987 Oct 22; 317(17):1098 (letter).
5. American Society of Plastic Surgeons: Evidence-based Clinical Practice Guideline: Reduction Mammoplasty 2011
6. The Center for Consumer Information & Insurance Oversight; Women's Health and Cancer Rights Act (WHCRA)

This guideline contains custom content that has been modified from the standard care guidelines and has not been reviewed or approved by MCG Health, LLC.

The Medical Policy Statement detailed above has received due consideration as defined in the Medical Policy Statement Policy and is approved.

Independent medical review – 06/2018